Biogen BIIB

NAS: BIIB | ISIN: US09062X1037   8/06/2023
308,88 USD (+1,31%)
(+1,31%)   8/06/2023

16 mei 2023 · Health Canada Accepts New Drug Submission for Lecanemab as Treatment for Early Alzheimer’s Disease · Persbericht

25 april 2023 · FDA Grants Accelerated Approval for QALSODY™ (tofersen) for SOD1-ALS, a Major Scientific Advancement as the First Treatment to Target a Genetic Cause of ALS · Persbericht

31 maart 2023 · Additional Detailed Analyses From Phase 2 Study 201 Of Lecanemab Published As Three Papers In Peer-Reviewed Journals · Persbericht

31 maart 2023 · Additional Detailed Analyses From Phase 2 Study 201 of Lecanemab Published as Three Papers in Peer-Reviewed Journals · Persbericht

31 maart 2023 · Eisai Presented New Analyses of ARIA and QOL on Lecanemab in Clarity AD at the AD/PD™ 2023 Annual Meeting · Persbericht

29 maart 2023 · New Data Presented at AD/PD™ 2023 Show Biogen’s BIIB080 (MAPT ASO) Substantially Reduced Tau Protein Levels in Patients with Early-stage Alzheimer’s Disease · Persbericht

23 maart 2023 · Biogen Provides Update on FDA Advisory Committee Meeting on Tofersen for SOD1-ALS · Persbericht

16 maart 2023 · Biogen Receives Favorable Decision from Court of Justice of the European Union Relating to TECFIDERA® (dimethyl fumarate) Regulatory Data and Marketing Protection · Persbericht

8 maart 2023 · Caroline Dorsa to Succeed Stelios Papadopoulos as Chair of Biogen Board of Directors · Persbericht

6 maart 2023 · FDA Accepts Eisai’s Filing of a Supplemental Biologics License Application and Grants Priority Review for Traditional Approval of LEQEMBI™ (lecanemab-irmb) for the Treatment of Alzheimer’s Disease · Persbericht

6 maart 2023 · FDA Accepts Eisai's Filing of a Supplemental Biologics License Application and Grants Priority Review for Traditional Approval of LEQEMBI™ (lecanemab-irmb) for the Treatment of Alzheimer's Disease · Persbericht

28 februari 2023 · Biologics License Application for Lecanemab Designated for Priority Review by China National Medical Products Administration · Persbericht

6 februari 2023 · Biogen and Sage Therapeutics Announce FDA Accepts Filing of New Drug Application and Grants Priority Review of Zuranolone in the Treatment of Major Depressive Disorder and Postpartum Depression · Persbericht

30 januari 2023 · Lecanemab Receives Priority Review Status in Japan · Persbericht

27 januari 2023 · Marketing Authorization Application for Lecanemab as Treatment for Early Alzheimer’s Disease Accepted by European Medicines Agency · Persbericht

27 januari 2023 · Marketing Authorization Application For Lecanemab As Treatment For Early Alzheimer's Disease Accepted By European Medicines Agency · Persbericht

16 januari 2023 · Eisai Files Marketing Authorization Application For Anti-Amyloid-Beta Protofibril Antibody Lecanemab For Early Alzheimer's Disease In Japan · Persbericht

11 januari 2023 · Eisai Submits Marketing Authorization Application For Lecanemab As Treatment For Early Alzheimer's Disease In Europe · Persbericht

7 januari 2023 · Eisai Submits Supplemental Biologics License Application to FDA for Traditional Approval of LEQEMBI™ (lecanemab-irmb) for the Treatment of Alzheimer's Disease · Persbericht

6 januari 2023 · FDA Approves LEQEMBI™ (lecanemab-irmb) Under the Accelerated Approval Pathway for the Treatment of Alzheimer's Disease · Persbericht

Mijn selecties